Detailed information for compound 605455

Basic information

Technical information
  • TDR Targets ID: 605455
  • Name: 2-chloro-N-(4-chlorophenyl)acetamide
  • MW: 204.053 | Formula: C8H7Cl2NO
  • H donors: 1 H acceptors: 1 LogP: 2.35 Rotable bonds: 3 Rule of 5 violations (Lipinski): 1
  • InChi: 1S/C8H7Cl2NO/c9-5-8(12)11-7-3-1-6(10)2-4-7/h1-4H,5H2,(H,11,12)
  • InChiKey: UDRCRMHFHHTVSN-UHFFFAOYSA-N  

Network

Synonyms

  • 2-chloro-N-(4-chlorophenyl)ethanamide
  • 3289-75-6
  • Acetanilide, 2,4'-dichloro-,
  • ZINC00165984
  • SBB004510
  • NSC8369
  • AI3-23540
  • Acetamide, 2-chloro-N-(4-chlorophenyl)-
  • NSC 8369

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Activities

Activity type Activity value Assay description Source Reference
CC50 (functional) = 5.7 uM Huh7 cytotoxicity for Pf inhibitors Novartis-GNF Malaria Box.
CC50 = 5.7 uM NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) ChEMBL. 18579783
EC50 (functional) = 0.342 uM W2 Pf proliferation inhibition Novartis-GNF Malaria Box.
EC50 (functional) = 0.342 uM NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay ChEMBL. 18579783
EC50 (functional) = 0.544 uM PF proliferation inhibition 3D7 Novartis-GNF Malaria Box.
EC50 (functional) = 0.544 uM NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay ChEMBL. 18579783
IFI promiscuity index = 0.0354 IFI promiscuity index Novartis-GNF Malaria Box.

Phenotypes

Whole-cell/tissue/organism interactions

Species name Source Reference Is orphan
Plasmodium falciparum ChEMBL23 18579783

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

No literature references available for this compound.
If you have references for this gene, please enter them in a user comment (below) or Contact us.

© 2013 – 2018 Trypanosomatics Lab | IIBIO - UNSAM
© 2005 – 2012 The TDR Drug Targets Network (WHO/TDR)

TDR Targets Development Release v6, Revision: 1335 (10.Aug.2018)
Contact Us: <info at tdrtargets org>